Offering was conducted by Citigroup, Jefferies and Leerink Partners
By Devika Patel
Knoxville, Tenn., Feb. 3 – Mirati Therapeutics, Inc. said the underwriters for its public sale of stock opted to exercise the deal’s $6.75 million greenshoe in full for total proceeds of $51.75 million. The deal was announced Jan. 28 and priced for $45 million with the greenshoe on Jan. 29.
The company sold 2,587,500 common shares at $20.00 per share. The price per share is a 2.25% discount to the Jan. 28 closing share price of $20.46. Of the shares, 337,500 were part of the fully exercised greenshoe.
Citigroup, Jefferies and Leerink Partners were the bookrunning managers.
Proceeds will be used for general corporate purposes, including clinical trials, research and development, working capital and general and administrative expenses.
The targeted oncology company is based in San Diego.
| Issuer: | Mirati Therapeutics, Inc.
|
| Issue: | Common stock
|
| Amount: | $51.75 million (including $6.75 million greenshoe)
|
| Shares: | 2,587,500
|
| Price: | $20.00
|
| Warrants: | No
|
| Bookrunners: | Citigroup, Jefferies and Leerink Partners
|
| Announcement date: | Jan. 28
|
| Pricing date: | Jan. 29
|
| Settlement date: | Feb. 3
|
| Stock symbol: | Nasdaq: MRTX
|
| Stock price: | $20.46 at close Jan. 28
|
| Market capitalization: | $286.15 million
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
